Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.37 |
| ▸ | NMBR | P28336 | 2/20 | 0.35 |
| ▸ | GRPR | P30550 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.34 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805345 | 0.87 | UBE2M (0.43) | UBE2MDCUN1D1NMBRGRPRKMT2A | |
| SCHEMBL6803558 | 0.87 | UBE2M (0.39) | UBE2MDCUN1D1NMBRGRPR | |
| SCHEMBL6186318 | 0.86 | SOAT1 (0.40) | UBE2MDCUN1D1NMBRGRPR | |
| SCHEMBL6185668 | 0.85 | MEN1 (0.37) | UBE2MDCUN1D1NMBRGRPRKMT2A | |
| SCHEMBL6801844 | 0.84 | UBE2M (0.41) | UBE2MDCUN1D1NMBRGRPRKMT2A | |
| SCHEMBL6808030 | 0.82 | UBE2M (0.39) | UBE2MDCUN1D1NMBRGRPRKMT2A | |
| SCHEMBL6183997 | 0.82 | NMBR (0.41) | UBE2MDCUN1D1NMBRGRPRKMT2A | |
| SCHEMBL6183517 | 0.81 | NMBR (0.37) | UBE2MDCUN1D1NMBRGRPR | |
| SCHEMBL6803628 | 0.81 | UBE2M (0.47) | UBE2MDCUN1D1NMBRGRPRKMT2A | |
| SCHEMBL6185224 | 0.80 | NSD2 (0.39) | NMBRGRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501800-A1 | BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003092670-A1 | BOMBESIN ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | UBE2M 3897/4885DCUN1D1 2124/4885NMBR 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.